Adaptive Liposome Compositions for Enhanced Cellular Delivery

A next-generation liposome composition that dynamically adapts to local pH conditions, enabling targeted and efficient delivery of therapeutic molecules to cells, while overcoming the limitations of traditional pH-sensitive liposomes.

The original patent disclosed pH-sensitive liposomes for delivering molecules to cells, but these liposomes had limited efficiency and selectivity. The new inventive concept addresses these limitations by introducing dynamically adaptive membrane structures that modulate fusion properties in response to local pH conditions, ensuring enhanced cargo release efficiency and targeted delivery.

The new inventive concept comprises pH-sensitive liposomes with dynamically adaptive membrane structures that respond to changes in local pH conditions. The liposomes are engineered to modulate their fusion properties, allowing for efficient cargo release and targeted delivery to cells. The pHLIP peptide is modified to include a pH-dependent cleavage site, enabling selective targeting and release of therapeutic payloads in response to changes in extracellular pH. The liposome composition can be tailored to an individual's specific disease profile and pH microenvironment, making it a promising platform for personalized medicine.

The new claims introduce the concept of dynamically adaptive membrane structures that respond to local pH conditions, which is a significant departure from the traditional pH-sensitive liposomes disclosed in the original patent. This inventive step enables enhanced cargo release efficiency and targeted delivery, making the new inventive concept a paradigm shift in the field of cellular delivery.

Alternative embodiments of the inventive concept could include the use of different pH-sensitive peptides, liposome compositions tailored to specific disease types, or the incorporation of additional targeting moieties. Variations could also include the use of different cargo molecules, such as nucleic acids or small molecules, or the development of liposome-based systems for real-time monitoring of cellular pH and cargo release.

The new inventive concept has significant commercial potential in the fields of cancer treatment, gene therapy, and personalized medicine. The ability to target specific cells and release therapeutic payloads in response to changes in extracellular pH could revolutionize the treatment of diseases. The market for liposome-based delivery systems is expected to grow significantly in the coming years, with the global market projected to reach $10.4 billion by 2025.